CHMP Approvals Signal Shift, JCA Device Rollout Begins

MarcusWelcome to Access Brief, the daily AI podcast on HEOR, HTA, and market access. I'm Marcus, with Sara. Today: CHMP's May approvals indicating development shifts, medical device JCAs launching, and AI topping ISPOR trends. Let's get into it.

SaraCHMP recommended eight medicines at its May meeting, but it's the thirteen indication extensions that tell the real story. Twenty-one clinical development programmes survived full scientific scrutiny in a single session.

MarcusThe approvals themselves are standard—nerandomilast for IPF, camizestrant for breast cancer, liraglutide for weight management. But thirteen extensions suggests sponsors are getting smarter about lifecycle management from initial approval.

SaraOr it reflects regulatory pathway optimization. Extensions require less de novo evidence generation than new molecular entities. We're seeing portfolio strategy shift toward indication expansion rather than novel assets.

MarcusThat's commercially driven thinking. The evidence bar for extensions isn't lower—it's different. These programmes still needed robust clinical packages. The real signal is that sponsors are building evidence strategies around platform molecules rather than betting everything on single indications.

SaraWhich makes perfect sense when you're facing JCA scrutiny. Better to establish your evidence base once and expand systematically than risk multiple novel assessments. But it also means we're moving toward a more concentrated pharmaceutical landscape.

MarcusThe oral semaglutide approval changes everything for GLP-1 market access. First oral formulation for weight management—that's not incremental innovation.

SaraIt's huge for adherence and patient preference, but the real question is whether NICE and other HTA bodies will differentiate on administration route. Injectable semaglutide already has established cost-effectiveness thresholds.

MarcusPatient preference has value, but quantifying it for HTA bodies remains problematic. The clinical efficacy data will drive the assessment, not convenience factors.

SaraMedical device JCAs start in June with five assessments anticipated. The HTA Coordination Group is scaling cautiously—two to five JSCs for devices versus eight to twelve for medicines.

MarcusSmart approach given the methodology gaps we've seen. Medical device evidence frameworks aren't as mature as pharmaceutical assessments. Starting small allows them to identify procedural issues before scaling to the anticipated fifty JCAs for medicinal products.

SaraBut five assessments won't generate meaningful precedent for device manufacturers. They need volume to establish consistent interpretation of evidence requirements across member states.

MarcusConsistency matters less than getting the framework right. Rushing device JCAs without proper methodology development would create more problems than it solves. The pharmaceutical JCAs have already shown capacity constraints.

SaraTrue, but device manufacturers need clarity on evidence expectations. Staying in pilot mode indefinitely serves no one's interests.

MarcusAI topped ISPOR's trends report, rising from number three. That's rapid acceleration in a field that typically moves incrementally.

SaraIt reflects real adoption across systematic literature reviews and predictive analyses. But I'm skeptical about AI's actual impact on evidence generation quality. Speed isn't everything in HEOR.

MarcusThe systematic review acceleration is genuine value. Manual literature searches and data extraction are massive resource drains. AI can democratize high-quality evidence synthesis for smaller organizations.

SaraDemocratization sounds positive until you consider that HTA bodies will raise evidence standards accordingly. If AI makes comprehensive reviews easier, they'll expect more comprehensive submissions. We're in an evidence arms race.

MarcusBut better evidence benefits everyone. If AI enables more thorough analysis of real-world data for post-market surveillance and outcomes research, that strengthens the entire evidence base.

SaraAssuming AI tools are validated and transparent. Black box algorithms generating evidence submissions won't satisfy regulatory scrutiny. The methodology matters more than the technology.

MarcusThe ISPOR discussions in Philadelphia focused heavily on AI integration with real-world evidence and patient-centered assessment. That suggests the field recognizes the validation challenges.

SaraRecognition and resolution are different things. We're still in the experimental phase.

MarcusCHMP's output suggests European drug development is becoming more strategic and evidence-focused.

SaraWhile device JCAs and AI adoption show the field is evolving rapidly—sometimes faster than our methodologies can keep pace.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.